Hi All,
Now they have discovered a somatic gene that will tell us if we will respond to Revlimid (and Thalidomide and Pomalidomide). The gene is called IZKF1 or Ikaros family zinc finger protein 1.
Low IZKF1 levels predict lack of immunemodulating drugs responsiveness and shorter overall survival.
This study is done in patients with Myeloma but other studies have showed that MDS patients are responding in the same way.
http://www.bloodjournal.org/content/124/4/536
Kind regards
Birgitta-A